| pubmed-article:17939651 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17939651 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:17939651 | lifeskim:mentions | umls-concept:C1522538 | lld:lifeskim |
| pubmed-article:17939651 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:17939651 | lifeskim:mentions | umls-concept:C2698650 | lld:lifeskim |
| pubmed-article:17939651 | lifeskim:mentions | umls-concept:C2000268 | lld:lifeskim |
| pubmed-article:17939651 | lifeskim:mentions | umls-concept:C2000269 | lld:lifeskim |
| pubmed-article:17939651 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:17939651 | pubmed:dateCreated | 2007-11-8 | lld:pubmed |
| pubmed-article:17939651 | pubmed:abstractText | Unsymmetrical bifunctional antitumor agent WMC79 was further optimized to generate compound 7b that not only inhibited the growth of many tumor cell lines, but caused rapid apoptosis. Unlike the parent compound, 7b is toxic to both p53 positive and negative cancer cells. It has potent in vivo activity against xenografts of human colon and pancreatic tumors in athymic mice. | lld:pubmed |
| pubmed-article:17939651 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17939651 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17939651 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17939651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17939651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17939651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17939651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17939651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17939651 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17939651 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:17939651 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:17939651 | pubmed:author | pubmed-author:StinsonSherma... | lld:pubmed |
| pubmed-article:17939651 | pubmed:author | pubmed-author:MichejdaChris... | lld:pubmed |
| pubmed-article:17939651 | pubmed:author | pubmed-author:CholodyWiesla... | lld:pubmed |
| pubmed-article:17939651 | pubmed:author | pubmed-author:Kosakowska-Ch... | lld:pubmed |
| pubmed-article:17939651 | pubmed:author | pubmed-author:HariprakashaH... | lld:pubmed |
| pubmed-article:17939651 | pubmed:author | pubmed-author:TarasovaNadya... | lld:pubmed |
| pubmed-article:17939651 | pubmed:author | pubmed-author:MeyerColinC | lld:pubmed |
| pubmed-article:17939651 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17939651 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17939651 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:17939651 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17939651 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17939651 | pubmed:pagination | 5557-60 | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:meshHeading | pubmed-meshheading:17939651... | lld:pubmed |
| pubmed-article:17939651 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17939651 | pubmed:articleTitle | Optimization of naphthalimide-imidazoacridone with potent antitumor activity leading to clinical candidate (HKH40A, RTA 502). | lld:pubmed |
| pubmed-article:17939651 | pubmed:affiliation | Molecular Aspects of Drug Design Section, Structural Biophysics Laboratory, Center for Cancer Research, NCI-Frederick, Frederick, MD 21702, USA. | lld:pubmed |
| pubmed-article:17939651 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17939651 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| pubmed-article:17939651 | pubmed:publicationType | Research Support, N.I.H., Intramural | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17939651 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17939651 | lld:pubmed |
